Latest news with #NEXGBerhad
Yahoo
20-05-2025
- Business
- Yahoo
NEXG Berhad's (KLSE:NEXG) market cap rose RM174m last week; retail investors who hold 37% profited and so did insiders
NEXG Berhad's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 51% of the business is held by the top 12 shareholders Insiders own 24% of NEXG Berhad Our free stock report includes 3 warning signs investors should be aware of before investing in NEXG Berhad. Read for free now. Every investor in NEXG Berhad (KLSE:NEXG) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are retail investors with 37% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. While retail investors were the group that benefitted the most from last week's RM174m market cap gain, insiders too had a 24% share in those profits. Let's take a closer look to see what the different types of shareholders can tell us about NEXG Berhad. See our latest analysis for NEXG Berhad Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. NEXG Berhad already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see NEXG Berhad's historic earnings and revenue below, but keep in mind there's always more to the story. Hedge funds don't have many shares in NEXG Berhad. The company's CEO Abu Bin Noordin is the largest shareholder with 7.8% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 5.9% and 4.7%, of the shares outstanding, respectively. A closer look at our ownership figures suggests that the top 12 shareholders have a combined ownership of 51% implying that no single shareholder has a majority. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our information suggests that insiders maintain a significant holding in NEXG Berhad. Insiders have a RM265m stake in this RM1.1b business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. The general public, who are usually individual investors, hold a 37% stake in NEXG Berhad. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Our data indicates that Private Companies hold 21%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research. It's always worth thinking about the different groups who own shares in a company. But to understand NEXG Berhad better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for NEXG Berhad you should be aware of, and 1 of them is a bit unpleasant. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
14-03-2025
- Business
- Yahoo
Global Penny Stocks: 3 Picks With Market Caps Over US$300M
Global markets have recently been impacted by tariff fears, inflation concerns, and growth uncertainties, leading to a decline in major U.S. stock indexes. Despite these challenges, the search for investment opportunities continues, particularly in areas that may offer unique growth potential. Penny stocks—often overlooked due to their association with smaller or newer companies—can still present valuable opportunities when they are built on strong financials and sound fundamentals. In this article, we explore several penny stocks that combine financial strength with the potential for significant returns, highlighting their relevance as an investment area today. Name Share Price Market Cap Financial Health Rating NEXG Berhad (KLSE:DSONIC) MYR0.255 MYR709.45M ★★★★★★ DXN Holdings Bhd (KLSE:DXN) MYR0.495 MYR2.46B ★★★★★★ Warpaint London (AIM:W7L) £3.575 £288.81M ★★★★★★ Foresight Group Holdings (LSE:FSG) £3.54 £402.66M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.70 SEK277.44M ★★★★★★ Lever Style (SEHK:1346) HK$1.31 HK$799.83M ★★★★★★ Bosideng International Holdings (SEHK:3998) HK$4.23 HK$47.57B ★★★★★★ EZZ Life Science Holdings (ASX:EZZ) A$1.61 A$75.95M ★★★★★★ Sarawak Plantation Berhad (KLSE:SWKPLNT) MYR2.28 MYR636.19M ★★★★★★ Next 15 Group (AIM:NFG) £2.93 £291.41M ★★★★☆☆ Click here to see the full list of 5,723 stocks from our Global Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Zhejiang CONBA Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and sales of medicines and general health products in China with a market cap of CN¥11.11 billion. Operations: The company's revenue is primarily generated from the Chinese market, amounting to CN¥6.46 billion. Market Cap: CN¥11.11B Zhejiang CONBA Pharmaceutical Ltd. has a market cap of CN¥11.11 billion and generates revenue primarily from China, totaling CN¥6.46 billion. The company demonstrates financial stability with short-term assets exceeding both short- and long-term liabilities, and more cash than total debt. However, its earnings have experienced negative growth over the past year despite significant growth in the previous five years. The company's dividend yield of 4.47% is not well covered by earnings or free cash flows, indicating potential concerns regarding sustainability. Additionally, profit margins have decreased to 7.5% from 11.2% last year due to large one-off gains impacting recent results. Dive into the specifics of Zhejiang CONBA PharmaceuticalLtd here with our thorough balance sheet health report. Gain insights into Zhejiang CONBA PharmaceuticalLtd's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Royal Group Co.,Ltd. operates in China, focusing on the processing, production, and sale of dairy products, with a market cap of CN¥2.85 billion. Operations: The company's revenue is entirely derived from its operations in China, amounting to CN¥2.16 billion. Market Cap: CN¥2.85B Royal Group Co., Ltd., with a market cap of CN¥2.85 billion, operates entirely within China, generating CN¥2.16 billion in revenue from dairy products. Despite being unprofitable, it has reduced its losses over the past five years and maintains a positive cash flow with sufficient runway for over three years. The company's short-term assets exceed both short- and long-term liabilities, providing some financial stability despite high net debt to equity ratio at 105.5%. Recent shareholder meetings approved proposals to adjust external guarantee limits and provide guarantees for village cooperatives, reflecting active investor engagement and strategic adjustments. Click to explore a detailed breakdown of our findings in Royal GroupLtd's financial health report. Evaluate Royal GroupLtd's historical performance by accessing our past performance report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Zhanjiang Guolian Aquatic Products Co., Ltd. operates in the aquaculture industry, focusing on the farming, processing, and distribution of seafood products with a market cap of CN¥4.28 billion. Operations: There are no specific revenue segments reported for this company. Market Cap: CN¥4.28B Zhanjiang Guolian Aquatic Products, with a market cap of CN¥4.28 billion, operates in the seafood industry and is currently unprofitable. Despite this, it has managed to reduce its losses by 2.1% annually over the past five years and maintains a positive free cash flow with a cash runway exceeding three years. Its short-term assets of CN¥3.5 billion comfortably cover both short- and long-term liabilities, suggesting financial resilience despite a high net debt to equity ratio of 42.1%. The management team is relatively new with an average tenure of 1.3 years, while the board is more seasoned at 4.2 years on average. Navigate through the intricacies of Zhanjiang Guolian Aquatic Products with our comprehensive balance sheet health report here. Assess Zhanjiang Guolian Aquatic Products' previous results with our detailed historical performance reports. Click through to start exploring the rest of the 5,720 Global Penny Stocks now. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:600572 SZSE:002329 and SZSE:300094. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
10-03-2025
- Business
- Yahoo
Global Penny Stocks To Watch In March 2025
Global markets have recently faced challenges, with U.S. stocks experiencing significant declines amid trade policy uncertainty and inflation concerns. Despite these headwinds, investors continue to explore opportunities in various sectors, including the often-overlooked realm of penny stocks. While the term 'penny stock' may seem outdated, it still represents a valuable investment area where smaller or newer companies can offer growth potential when supported by strong financials and fundamentals. Name Share Price Market Cap Financial Health Rating NEXG Berhad (KLSE:DSONIC) MYR0.27 MYR751.18M ★★★★★★ Warpaint London (AIM:W7L) £3.65 £294.87M ★★★★★★ DXN Holdings Bhd (KLSE:DXN) MYR0.505 MYR2.51B ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.39 SGD9.44B ★★★★★☆ EZZ Life Science Holdings (ASX:EZZ) A$1.69 A$81.61M ★★★★★★ Sarawak Plantation Berhad (KLSE:SWKPLNT) MYR2.28 MYR636.19M ★★★★★★ Angler Gaming (NGM:ANGL) SEK3.79 SEK284.19M ★★★★★★ Next 15 Group (AIM:NFG) £2.92 £290.41M ★★★★☆☆ Cloudpoint Technology Berhad (KLSE:CLOUDPT) MYR0.77 MYR409.33M ★★★★★★ Lever Style (SEHK:1346) HK$1.28 HK$844.27M ★★★★★★ Click here to see the full list of 5,709 stocks from our Global Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Liuzhou Chemical Industry Co., Ltd. is a company engaged in the production and sale of hydrogen peroxide in China, with a market capitalization of approximately CN¥2.51 billion. Operations: The company's revenue segment is primarily derived from the Chemical Industry, generating CN¥178.44 million. Market Cap: CN¥2.51B Liuzhou Chemical Industry's market capitalization stands at approximately CN¥2.51 billion, with a revenue segment primarily from the chemical industry generating CN¥178.44 million. The company has no debt, and its short-term assets of CN¥484.1 million significantly exceed its liabilities, indicating strong liquidity. Despite a volatile share price recently, earnings growth has been robust at 381.3% over the past year, surpassing both its historical average and industry benchmarks. Its Price-To-Earnings ratio of 26.9x suggests it may be undervalued compared to the broader Chinese market average of 38.5x, although Return on Equity remains relatively low at 16.9%. Click here to discover the nuances of Liuzhou Chemical Industry with our detailed analytical financial health report. Gain insights into Liuzhou Chemical Industry's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Wenfeng Great World Chain Development Corporation operates a commercial retail chain in China, with a market cap of CN¥5.58 billion. Operations: The company's revenue primarily comes from its operations in China, totaling CN¥1.93 billion. Market Cap: CN¥5.58B Wenfeng Great World Chain Development's market cap is CN¥5.58 billion, with revenue of CN¥1.93 billion from its Chinese retail operations. The company faces challenges with a low Return on Equity of 2.6% and declining earnings, down 25.6% annually over five years. Short-term liabilities exceed short-term assets (CN¥1.8B vs CN¥1.3B), raising liquidity concerns despite having more cash than debt and sufficient interest coverage by profits. A dividend yield of 2.39% is not well supported by earnings or free cash flow, while the management team and board are relatively inexperienced with average tenures under three years each. Navigate through the intricacies of Wenfeng Great World Chain Development with our comprehensive balance sheet health report here. Assess Wenfeng Great World Chain Development's previous results with our detailed historical performance reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Harbin Gloria Pharmaceuticals Co., Ltd focuses on the research, development, production, and sale of pharmaceutical products mainly in China with a market cap of CN¥5.52 billion. Operations: Harbin Gloria Pharmaceuticals Co., Ltd has not reported any specific revenue segments. Market Cap: CN¥5.52B Harbin Gloria Pharmaceuticals, with a market cap of CN¥5.52 billion, has recently become profitable, yet its Return on Equity remains low at 4.7%. The company's short-term liabilities slightly exceed its short-term assets (CN¥871.9M vs CN¥870.4M), indicating tight liquidity management despite having more cash than total debt and reducing its debt-to-equity ratio significantly over five years. Recent board changes reflect investor activism with new director appointments aiming to strengthen governance. Although earnings have grown significantly over the past five years, the presence of large one-off gains impacts financial clarity and stability assessments for potential investors in this volatile space. Click to explore a detailed breakdown of our findings in HARBIN GLORIA PHARMACEUTICALS' financial health report. Gain insights into HARBIN GLORIA PHARMACEUTICALS' outlook and expected performance with our report on the company's earnings estimates. Investigate our full lineup of 5,709 Global Penny Stocks right here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Jump on the AI train with fast growing tech companies forging a new era of innovation. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SHSE:600423 SHSE:601010 and SZSE:002437. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
